Raymond James analyst Andrew Cooper raised the firm’s price target on Azenta (AZTA) to $45 from $35 and keeps an Outperform rating on the shares following a fiscal Q4 report that the firm describes as “generally in line to above hopes.” An investor day in just a few weeks should “shed major light on the longer-term view,” says the analyst, who thinks it will be in the mid-single-digit-plus organic revenue range with a path to margins breaching 20%, leaving the firm “optimistic on the trajectory.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZTA:
- Azenta upgraded to Hold from Sell at Nephron Research
- Azenta, Inc. Reports Strong Fiscal 2025 Results
- Azenta, Inc. Reports Resilient Earnings Amid Challenges
- Azenta’s Strong Q4 Performance and Strategic Initiatives Drive Buy Rating and Increased Price Target
- Azenta’s Mixed Performance: Growth in Multiomics Amidst US Market Challenges Leads to Hold Rating
